Why One Analyst Thinks LLY Is Worth $850 While the Rest of Wall Street Targets $1,216

HSBC downgraded Eli Lilly to Reduce and cut its price target to $850 from $1,070, implying a material downside versus current levels; LLY shares have fallen ~9% over the past month and ~13% YTD. HSBC argues the obesity TAM is $80–120B by 2032 (vs. $150B+ expectations), warns of accelerating GLP-1 pricing pressure (U.S. realized prices down ~10% in Q3 2025 partly offset by +62% volume) and highlights concentration risk (Mounjaro + Zepbound = $11.67B of $19.29B Q4 2025 revenue). For the $850 bear case to materialize, orforglipron must underperform, pricing must deteriorate faster than volume growth, and the stock would need to de-rate from its ~43x trailing P/E.

Analysis

LLY’s earnings sensitivity is asymmetric: high concentration in two obesity franchises creates outsized EPS leverage to small moves in realised price or persistence. A mid-single-digit deterioration in net realized price or a modest slip in adherence can compress operating margins materially because fixed SG&A and newly scaled COGS capacity don’t re-contract quickly, making valuation highly P/E-dependent over 12–24 months.

Payer and channel dynamics are the likely accelerant for downside: PBMs and payers can shift the realized price mix faster than physicians change prescribing behavior, via step edits, formulary placement and higher rebates. Expect a two-phase mechanism — near-term realized-price hits from contracting and rebates (3–9 months), followed by a medium-term volume rebalancing as access expands but net ASPs settle lower (9–24 months).

Supply-side capacity builds are a non-obvious risk multiplier. New API/CMO capacity and oral formulation launches can create a rapid oversupply-to-demand mismatch, catalysing price compression beyond negotiated rebates as manufacturers compete for share; this is a 12–36 month pathway to secular ASP decline. Conversely, durable real-world adherence or a successful oral product would reverse de-rating and lock in a structural premium, but that requires clear persistence data over multiple quarters.

Monitor three catalysts: payer contracting cadence and CMS guidance (quarters), real-world persistence/retention readouts (rolling 3–12 months), and commercial rollout metrics for the oral candidate (12–24 months). The stock’s path will be driven more by net price dynamics and persistence than headline volume growth; investors who treat volume as a stable cash-flow lever will be surprised on the downside.

Key Decisions for Investors

• Pair trade (6–12 months): Short LLY equity vs long NVO (dollar-neutral). Size the short at 0.5x fund beta and the long to neutralize market exposure. R/R: target 20–30% relative downside of LLY vs NVO; stop if LLY outperforms NVO by >10% over a rolling 30-day window. Rationale: hedged exposure to obesity market share shifts and relative pricing power.
• Directional options (12–18 months): Buy a put spread on LLY (long 1-year+ put, short a deeper OTM put) sized to risk 1–2% of portfolio. Aim for a structure that captures a 25–35% downside move while limiting premium paid. Exit on confirmation of improving persistence metrics or if realized price stabilizes in two consecutive quarters.
• Long payers/beneficiaries (3–12 months): Overweight UNH (or large national payer) to capture structural benefit from lower net GLP-1 costs and reduced medical spend. Position size 2–4% of portfolio; take profits if GLP-1 net ASPs compress less than 5% sequentially across two quarters.
• Event-driven volatility trade (0–3 months): Buy near-term LLY puts into the next earnings/Medicare/PBM contract window and sell longer-dated calls to finance premium if comfortable with assignment. Target a 2:1 reward-to-risk by risking defined premium vs potential 15–25% downside on a negative print; unwind on directional clarity post-catalyst.